The cost-effectiveness of screening for type 2 diabetes

JAMA

Volumn 280, Issue 20, 1998, Pages 1757-1763

  Engelgau, Michael M ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; MODEL; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING; SYSTEM ANALYSIS; TREATMENT OUTCOME;

EID: 0032567110     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.20.1757     Document Type: Article

References (55)

1. Centers for Disease Control and Prevention. National diabetes awareness month, November 1997. MMWR Morb Mortal Wkly Rep. 1997;46:1013.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
3. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15:815-819.
4. Harris M. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642-652.
5. Harris MI, Modan M. Screeningfor NIDDM: why is there no national program? Diabetes Care. 1994; 17:440-444.
6. Wei M, Haffner S, Stern M. High fasting glucose as a predictor of total and cardiovascular disease (CVD) mortality in patients with NIDDM [abstract]. Diabetes. 1997;46(suppl 1):137A.
7. American Diabetes Association. Clinical practice recommendations 1998. Diabetes Care. 1998;21 (suppl 1):S20-S22.
8. Engelgau MM, Aubert RE, Thompson TJ, Herman WH. Screening for NIDDM in nonpregnant adults. Diabetes Care. 1995;18:1606-1618.
9. Knowler WC. Screening for NIDDM: opportunities for detection, treatment, and prevention. Diabetes Care. 1994;17:445-449.
10. Stewart-Brown S, Farmer A. Screening could seriously damage your health. BMJ. 1997;314:533.
11. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
12. Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1468-1478.
13. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA. 1996;276:1409-1415.
14. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM, I. Diabetes Care. 1997;20:725-734.
15. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM, II: analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-744.
16. National Health Interview Survey [database on CD-ROM]. Washington, DC: US Government Printing Office; 1993.
17. McDowell A, Engel A, Massey JT, Maurer K. Plan and operation of the Second National Health and Nutrition Examination Survey, 1976-1980. Vital Health Stat 1. 1981;1:1-144. DHHS publication PHS 81-1317.
18. Klein R, Klein BEK, Moss SE. Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care. 1993;16:1325-1330.
19. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121(1 pt 2):293-298.
20. Turner R, Cull C, Holman R, for the UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) 17. Ann Intern Med. 1996; 124(1 pt 2):136-145.
21. Abraraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VAC-SDM). Diabetes Care. 1995;18:1113-1123.
22. Herman WH, Ali MA, Aubert RE, et al. Diabetes mellitus in Egypt. Diabetes Med. 1995;12:1126-1131.
23. Javitt JC, Aiello LP, Chiang Y, et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Diabetes Care. 1994;17:909-917.
24. Nelson RG, Knowler WC, Pettitt DM, Hanson RL, Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care. 1995;18:182-187.
25. Ballard DJ, Humphrey LL, Melton LJ III, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Diabetes. 1988;37:405-412.
26. Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1989;111:788-796.
27. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. Neurology. 1993;43:817-824.
28. Humphrey LL, Palumbo PJ, Butters MA, et al. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med. 1994;154:885-892.
29. Eckman MH, Greenfield, S, Mackey WC, et al. Foot infections in diabetic patients. JAMA. 1995; 273:721-720.
30. Health Care Financing Administration. Research Report: End Stage Renal Disease, 1994. Baltimore, Md: Health Care Financing Administration; 1996.
31. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the US population aged 20-74 yr. Diabetes. 1987;36:523-534.
32. Dong F, Narayan V, Manninen D, et al. Higher prevalence of undiagnosed diabetes among US minority groups may be explained by higher prevalence of risk factors [abstract]. Diabetes. 1997;46 (suppl 1):77A.
33. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
34. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS), VIII: study design, progress and performance. Diabetologia. 1991;34:877-890.
35. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1995;28:103-117.
36. American Diabetes Association. Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1995;18:1510-1518.
37. Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995;332:1210-1217.
38. Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes. In: National Diabetes Data Group, eds. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health; 1995. NIH publication 95-1468.
39. Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiological Study of Diabetic Retinopathy. Arch Intern Med. 1995; 155:745-754.
40. Nathan DM, Crofford OB, Lachin JM. The effect of intensive treatment of diabetes mellitus. N Engl J Med. 1994;330:642.
41. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes. 1992;41:202-208.
42. Barrett-Connor E. Does hyperglycemia really cause coronary heart disease? Diabetes Care. 1997; 20:1620-1623.
43. Stern M. Glycemia and cardiovascular risk [editorial]. Diabetes Care. 1997;20:1501-1503.
44. Medical Economics. Red Book. Montvale, NJ: Medical Economics Co; 1996.
45. Balkin SW. Lower limb amputation and the diabetic foot. JAMA. 1995;273:185.
46. American Heart Association. Heart and Stroke Facts: Statistical Supplement. Dallas, Tex: American Heart Association; 1995.
47. Dasbach EJ, Fyback DG, Thornbury JR. Health utility preference differences [abstract]. Med Decis Making. 1992;12:4.
48. Eastman R, Dasbach EJ. Sensitivity of diabetes model to mortality assumptions. Paper presented at: American Diabetes Association Annual Meeting; June 21, 1997; Boston, Mass.
49. Peters AL, Davidson MB, Schriger L, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus. JAMA. 1996;276:1246-1262.
50. Thompson TJ, Engelgau MM, Hegazy M, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med. 1996;13: 337-340.
51. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening. Breast Cancer Res Treat. 1993;25:113-118.
52. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med. 1990;112:192-202.
53. Coppleson LW, Brown B. The prevention of carcinoma of the cervix. Am J Obstet Gynecol. 1976; 125:153-159.
54. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-983.
55. Granata AV, Hillman AL. Competing practice guidelines. Ann Intern Med. 1998;128:56-63.